MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/aos.70168

Медицинская библиотека · Acta ophthalmologica · 2026

Timing and duration of glucagon-like peptide-1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy.

Niazi Siar, Gnesin Filip, Jawad Baker Nawfal, Niazi Zia, Yazdanfard Puriya Daniel Wuertz, Toft-Petersen Anne P, Sørensen Kathrine Kold, Meaidi Amani, Subhi Yousif, Torp-Pedersen Christian

СтатьяПеревод в очереди

Аннотация

PURPOSE: To investigate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration.

METHODS

This nationwide registry-based nested case-control study utilizedz Danish health registries (1996-2023). Among 201 776 metformin-treated adults initiating second-line antihyperglycaemic therapy, 123 incident NAION cases were matched to 4920 controls by birth year and sex (incidence-density sampling). Conditional logistic regression estimated adjusted hazard rate ratios (HRs) for GLP-1RA exposure by recency (current 0-90 days; recent 91-365 days) and cumulative duration, adjusting for socio-economic factors, hypertension, hypercholesterolaemia, sleep apnoea, and diabetes duration.

RESULTS

GLP-1RA use occurred in 63/123 cases (51.2%) and 1688/4920 controls (34.3%). Ever use was associated with a higher NAION rate than other second-line therapies (HR 2.13, 95% CI: 1.43-3.18). Current use was associated with elevated rates (HR 2.28, 95% CI: 1.49-3.48), whereas the estimate for recent use was imprecise (HR 1.69, 95% CI: 0.88-3.25). By cumulative duration, no clear evidence of an increase was seen within 0-½ years (HR 0.80, 95% CI: 0.32-2.05), and rates were highest at ½-1 year (HR 3.63, 95% CI: 2.06-6.40) and 1-1½ years (HR 3.52, 95% CI: 1.73-7.17). Findings were consistent after HbA1c adjustment and in a new-user analysis.

CONCLUSION

GLP-1RA use is associated with a higher NAION rate in type 2 diabetes. This association appears time-dependent, being most pronounced during current treatment and peaking after 6-18 months of cumulative exposure.

Для цитирования: Niazi Siar, Gnesin Filip, Jawad Baker Nawfal, Niazi Zia, Yazdanfard Puriya Daniel Wuertz, Toft-Petersen Anne P, Sørensen Kathrine Kold, Meaidi Amani, Subhi Yousif, Torp-Pedersen Christian. Timing and duration of glucagon-like peptide-1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy.. Acta ophthalmologica. 2026. DOI: 10.1111/aos.70168.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.